https://www.selleckchem.com/pr....oducts/pf-06873600.h
05). No patient had symptomatic COVID‑19. There was no association among patients' age, ****, drugs used for IBD, or disease activity and the occurrence of IgG antibodies. Patients with IBD may be at higher risk of developing SARS‑CoV‑2 infection, defined as the presence of elevated levels of anti-SARS‑CoV‑2 IgG antibodies, but not of having a symptomatic and / or severe course of COVID‑19 compared with healthcare professionals without IBD. Patients with IBD may be at higher risk of developing SARS‑CoV‑2 infection, defined as the pre
پسندیدن
اظهار نظر
اشتراک گذاری
